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Background
k
The National Comprehensive Cancer Network 
recommends for high-risk stage II and stage III colon 
cancer patients to receive chemotherapy after 
colectomy.1 There are currently multiple combination 
chemotherapy regimens available for colon cancer 
treatment. Decision of regimen is determined on an 
individual patient basis.1 Not many studies have 
evaluated the effectiveness and financial costs of these 
regimens. Our study aims to evaluate these regimens in 
terms of both health outcomes and financial burden.
Research Question
k
Which chemotherapy regimen is the most cost-
effective, meaning lowest average cost in 




We used the Surveillance, Epidemiology, and End 
Results (SEER) linked with Medicare database for this 
study. Patients 66-100 years old diagnosed with colon 
cancer between 2007 and 2015 who survived at least 6 
months since diagnosis and received surgery followed 
by chemotherapy were included (cohort selection 
criteria is listed in Figure 1). We evaluated 4 types of 
regimens: 5-FU/LV (fluorouracil, leucovorin), 
capecitabine, FLOX (fluorouracil, leucovorin, 
oxaliplatin), and mFOLFFOX6 (folinic acid, fluorouracil, 
oxaliplatin). Regimen and total cost per patient were 
estimated. Linear regression was used to compare 
differences in mean costs. Patients’ survival was 
estimated using the Kaplan-Meier method and a 
multivariable Cox regression model was used to 
compare survival among different regimens while 
adjusting for patient characteristics. All analysis was 
done in SAS EG 7.11.
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Relation to Cancer Prevention
k
Tertiary cancer prevention focuses on patients already 
affected by cancer progression. These patients have 
many needs including various treatments, therapies, and 
support. Our study aims to provide support and 
information to these patients about cost-effectiveness of 
various treatment options. To ensure quality of life after 
cancer remission, financial burden must be taken into 
consideration to encourage cancer treatment completion 
and leave fewer lasting effects of treatment.
Conclusion 
Patterns of chemotherapeutic colon cancer regimen 
use have changed overtime as the FDA approved 
new drugs between 2007 and 2015. These changes 
resulted in 5-FU/LV decreasing over time in favor of 
newer treatments, and capecitabine increasing over 
time. Of the four regimens considered, 5-FU/LV had 
the lowest regimental costs. However, total cancer 
treatment costs were similar among the four 
regimens. There were no statistically significant 
differences in patients’ survival comparing 5-FU/LV, 
capecitabine, FLOX, and mFOLFOX6.
Future Directions
To calculate quality-adjusted life-years (QALYs) and the 
incremental cost-effectiveness ratio (ICER) for the four 
regimens in order to directly compare cost-effectiveness.
Implications
k
Implications of this study affect patients, physicians, and 
drug development. This information can be used by 
physicians to inform patients of potential results of their 
treatment course, including financial burden. Affordable 
cancer treatment is essential to patient completion and 
positive health outcome in order to reach ideal survival.
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k
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Figure 2. Kaplan-Meier Curve for Cause-specific Survival by 
Regimens Adjusted for Covariates
Cause-specific Survival
Hazard Ratio 95% CI p-value
Regimen 5-FU/LV ref
Capecitabine 1.01 0.86 1.20 0.880
FLOX 1.07 0.92 1.24 0.389
mFOLFOX6 1.09 0.79 1.49 0.611
Variables 5-FU/LV Capecitabine FLOX mFOLFOX6 P
n=993 n=1809 n=3799 n=324
row % row % row % row %
Stage
II 19.10% 32.00% 44.80% 4.00% <.0001
III 12.90% 24.40% 57.80% 4.90%
Year of diagnosis
2007 19.90% 21.20% 56.90% 1.90% <.0001
2008 18.70% 20.30% 59.60% 1.40%
2009 13.50% 21.40% 62.70% 2.40%
2010 15.20% 24.90% 57.40% 2.50%
2011 11.50% 28.50% 53.80% 6.10%
2012 11.20% 27.30% 50.70% 10.70%
2013 12.10% 30.80% 51.30% 5.80%
2014 13.00% 29.20% 52.20% 5.50%
2015 11.60% 34.60% 46.50% 7.30%
Gender
Female 14.80% 28.20% 52.50% 4.50% <.0001
Male 13.80% 23.70% 57.60% 4.80%
Duration of 
chemotherapy
<=90days 19.20% 44.20% 33.00% 3.60% <.0001
91-180days 12.70% 27.80% 54.40% 5.10%
181-365days 18.50% 20.10% 55.60% 5.80%
366+days 10.20% 15.20% 70.90% 3.70%
Male 13.80% 23.70% 57.60% 4.80%
Cost $ (Median)
Regimen 5370.8 10022.9 27710.2 13684.8 *
Total 113277.8 109280.9 130304.2 115058.1 *
*P-value from ANOVA test was <0.05 for cost
Table 1. Patients’ characteristic distributions and median cost 
by regimens
Table 4. Association between cancer cause-specific survival 
and chemotherapy regimens in multivariable Cox Regression 
Model* 
*Covariates adjusted in the multivariable model for Table 3 and 4 
were: age, gender, race, region, education, income, Charlson 
comorbidity, stage, and treatment duration
Year 5-FU/LV Capecitabine FLOX mFOLFOX6
1 94.6% 93.7% 96.1% 95.2%
2 82.9% 83.3% 87.3% 86.7%
3 75.2% 73.9% 77.7% 72.2%
4 68.7% 66.2% 69.5% 64.6%
5 65.0% 61.9% 64.0% 60.6%
Table 3. Adjusted Survival Probabilities by Regimens*
